HOME >> BIOLOGY >> NEWS
Achillion and UMBC collaboration identifies new class of agents with potential to treat HIV

Baltimore, MD and New Haven, CT, April 1, 2003 In a successful partnership between industry and academia, researchers from The University of Maryland, Baltimore County (UMBC) and Achillion Pharmaceuticals today announced the discovery of a new target on the HIV molecule that could potentially lead to a new class of anti-viral drugs to fight the virus that causes AIDS. The study, headed by Dr. Michael Summers, UMBC professor of chemistry/biochemistry and Howard Hughes Medical Institute (HHMI) Investigator, is featured on the cover of this week's Journal of Molecular Biology.

"The greatest challenge in treating HIV today is drug resistance brought on when the virus mutates and renders existing drugs ineffective at stopping viral replication," said Dr. Summers. "Our research has led to the identification of a new class of compounds that inhibit a novel target in HIV. These compounds disrupt the assembly of the HIV-1 capsid protein, which is a vital step in changing immature, non-infectious HIV into its mature, infectious form."

"Investigators around the world have been looking at the HIV-1 capsid protein as a potential drug target for more than a decade, and we are therefore particularly pleased to finally have solid leads to guide these efforts," said William G. Rice, Ph.D., Achillion's CEO. "While we are encouraged by the laboratory tests of the compounds we've identified so far, additional testing needs to be undertaken before this approach can be tested in humans."

Dr. Summers and his team identified the target at the UMBC HHMI Lab and discovered a number of compounds that bound to a specific area of the capsid protein thought to play a key role in the assembly process necessary for HIV to mature to its infectious form. The identification process leveraged the nuclear magnetic resonance (NMR) technology resources and target validation expertise at Summers' HHMI laboratory.

Once the new capsid assembly target and compounds inhibitin
'"/>

Contact: Amy Enders
aenders@achillion.com
203-401-3135
Achillion Pharmaceuticals
1-Apr-2003


Page: 1 2

Related biology news :

1. North Shore-LIJ research collaboration with Correlogic Systems to advance ovarian cancer blood test
2. OneWorld Health CEO outlines mutually beneficial collaborations between industry, nonprofits at BIO
3. Institute for Systems Biology, Pacific Northwest National Laboratory announce collaboration
4. NCI awards $7.6 million to prostate cancer research collaboration
5. Research collaboration identifies gene essential to puberty
6. Scripps team part of collaboration that reveals first ecological genomic blueprints
7. US-EC Biotech Task Force keys on research, collaboration
8. JGI and Diversa Corp. announce large-scale microbial sequencing collaboration
9. Web-based collaboration links labs to supercomputers
10. UC & sister institutions form Institute Without Walls for transdisciplinary collaborations
11. Citing human obligation, AAAS CEO urges U.S.-Cuban collaboration

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/27/2019)... (PRWEB) , ... August 27, 2019 , ... ... company, announced today new opportunities to improve genetic testing guidelines. In the largest ... improve the guidelines to identify more at-risk patients. , Clinicians use guidelines ...
(Date:8/23/2019)... ... August 22, 2019 , ... R121 ... their acquisition in June of 2018. Along with the name change, this rebranding ... “Our goal was to create a cohesive brand that blended our core foundation ...
(Date:8/19/2019)... ... August 19, 2019 , ... Since the microscope was first ... dimensional slices which are placed on microscope slides, stained and visualized by a ... features such as vasculature and thus researchers in the last few years have ...
Breaking Biology News(10 mins):
(Date:9/11/2019)... ... 10, 2019 , ... An upcoming episode of Advancements with ... genome sequencing analysis. Check your local listings for more information. , Advancements will ... Consulting and will explore its revolutionary pathogenic DNA analysis technology, which predicts in ...
(Date:9/9/2019)... ... September 09, 2019 , ... Visikol CEO Dr. Michael Johnson recently gave a ... best to characterize 3D cell culture models. The inherent problem of characterizing 3D cell ... opaque to image through and therefore traditional wide-field or even confocal microscopy only tells ...
(Date:9/8/2019)... ... 05, 2019 , ... Spartan Bioscience, the leader in on-demand ... Shopify, has been named Chief Financial Officer. , Spartan has also named ... advisors. Additionally, Spartan has hired Steve Edgett as Executive Vice President to lead ...
(Date:9/2/2019)... and LIÉGE, Belgium (PRWEB) , ... September 02, ... ... solutions for epigenetics research and in vitro diagnostics, has launched the industry’s first ... uncover the underlying biological meaning of epigenetic data and other data types. , ...
Breaking Biology Technology:
Cached News: